Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up.
Selleng
Sixten
S
Greinacher
Andreas
A
Ittermann
Till
T
Wollert
Hans-Georg
HG
D001323:Autoantibodies / Q000097:blood*; D001026:Coronary Artery Bypass; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000276:immunology*; D005500:Follow-Up Studies; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced / Q000276:immunology; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000276:immunology*; D011183:Postoperative Complications / Q000139:chemically induced* / Q000276:immunology*; D012306:Risk; D013927:Thrombosis / Q000139:chemically induced / Q000276:immunology
D001323:Autoantibodies; D005343:Fibrinolytic Agents; D010978:Platelet Factor 4; D006493:Heparin